The Lancet Oncology,

[Comment] Anti-KIR3DL2 therapy in the treatment of Sézary syndrome

In The Lancet Oncology, Bagot and colleagues1 present the results of an international, multicentre, open-label, phase 1 study evaluating IPH4102 in patients with relapsed or refractory cutaneous T-cell lymphoma. IPH4102 is a humanised, first-in-class, monoclonal antibody that targets KIR3DL2, a cell surface protein widely expressed in cutaneous T-cell lymphoma, and predominantly in its leukaemic form, Sézary syndrome. The binding of the drug with the target induces antibody-dependent cell cytotoxicity...

The Lancet Oncology

6h

[Articles] IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial

IPH4102 is safe and shows encouraging clinical activity in patients with relapsed or refractory cutaneous T-cell lymphoma, particularly those with Sézary syndrome. If confirmed in future trials, IPH4102 could become a novel treatment option for these patients. A multi-cohort, phase 2 trial (TELLOMAK) is underway to confirm the activity in patients with Sézary syndrome and explore the role of IPH4102 in other subtypes of T-cell lymphomas that express KIR3DL2.

The Lancet Oncology

6h